TYPE 1 DIABETES GENETICS CONSORTIUM

1 型糖尿病遗传学联盟

• 批准号: 7603538
• 负责人: Catherine Pihoker
• 金额: $ 0.1万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603538
• 关键词: Accounting; Affect; African American; Age; American; Asia; Australia; Blood specimen; Class; Clinical; Collection; Complex; Complications of Diabetes Mellitus; Computer Retrieval of Information on Scientific Projects Database; Data; Diabetes Mellitus; Diagnosis; Disease; Ethnic Origin; Europe; Family; Family member; Funding; Genes; Genetic; Genetic Polymorphism; Genetic Risk; Grant; Individual; Institution; Insulin-Dependent Diabetes Mellitus; Latin America; Low Prevalence; MHC Class I Genes; Mexican Americans; North America; Parents; Play; Population; Prevalence; Purpose; Questionnaires; Recruitment Activity; Research; Research Personnel; Resources; Risk; Role; Siblings; Source; Testing; Twin Studies; United States National Institutes of Health; base; clinical phenotype; design; diabetes mellitus genetics; diabetes risk; gene interaction; genetic resource; international center; proband

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, international, organized effort designed to identify the genes that determine one's risk of developing diabetes. From family and twin studies, it is known that the genetic basis of type 1 diabetes is complex, including genes with large and small effect. It is established that HLA Anti class II and class I genes play a major role in determining diabetes risk. However, it is apparent that HLA accounts for only approximately 50% of the total genetic risk of type 1 diabetes. Over the past two decades, several other genes and gene polymorphisms have been identified that contribute to diabetes risk. However, it has been difficult to fully assess the magnitude of individual gene effects and gene interactions due to limited clinical and genetic resources. In this study, multiple family members will be recruited in an organized, consistent fashion. The study will take place in North America (at least 9 centers, including CHRMC / Seattle), Europe, Asia, Australia, and Latin America. Families will be recruited as affected sib pairs (ASP), meaning two or more siblings with type 1 diabetes. Parents of ASP and other, unaffected siblings will also be invited to participate in the study. Data will be collected on clinical phenotype (e.g. age at diagnosis, ethnicity, body habitus, diabetes complications) on all subjects with diabetes. HLA class I and II genes, and at least 4 additional promising genetic loci, will be examined in each family member, in the context of disease status. Data are collected as blood samples and questionnaires, for research purposes only. Recently recruitment has been expanded to low prevalence trio families (proband and both parents) in the North American Network. Trios will be collected only in those populations where the prevalence of type 1 diabetes is low - that is, in populations where families with two affected offspring are very rare. Therefore, the trio collections will focus on Mexican-American and African-Americans. The testing will be exactly the same as for ASP families.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项多中心、国际性、有组织的工作，旨在识别决定一个人患糖尿病风险的基因。 从家族和双胞胎研究中得知，1型糖尿病的遗传基础很复杂，包括影响大小的基因。 已确定 HLA 抗 II 类和 I 类基因在确定糖尿病风险方面发挥着重要作用。 然而，很明显，HLA 仅占 1 型糖尿病总遗传风险的约 50%。 在过去的二十年中，已经确定了其他几个与糖尿病风险有关的基因和基因多态性。 然而，由于临床和遗传资源有限，很难充分评估个体基因效应和基因相互作用的程度。 在这项研究中，将以有组织、一致的方式招募多名家庭成员。 该研究将在北美（至少 9 个中心，包括 CHRMC/西雅图）、欧洲、亚洲、澳大利亚和拉丁美洲进行。 家庭将被招募为受影响的同胞对 (ASP)，即两个或更多患有 1 型糖尿病的兄弟姐妹。 ASP 的父母和其他未受影响的兄弟姐妹也将被邀请参加这项研究。 将收集所有糖尿病受试者的临床表型数据（例如诊断年龄、种族、身体习惯、糖尿病并发症）。 将根据疾病状况对每个家庭成员进行 HLA I 类和 II 类基因以及至少 4 个其他有希望的遗传位点检查。 数据以血样和问卷形式收集，仅供研究之用。 最近，北美网络的招募范围已扩大到低患病率三人家庭（先证者和父母双方）。 Trios 只会在 1 型糖尿病患病率较低的人群中收集，即具有两个受影响后代的家庭非常罕见的人群。 因此，三人组的收藏将重点关注墨西哥裔美国人和非裔美国人。 测试将与 ASP 系列完全相同。